AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34995804
Drug: Carbohydrate loading
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate loading with individualized supplemental insulin
Trial: 35751892
Drug: Liraglutide plus
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide plus dapagliflozin (0.6 mg liraglutide and 5 mg dapagliflozin once a day)
Trial: 33969592
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg, daily)
Trial: 32598387
Drug: Drospirenone (DRSP)
RxNorm normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drospirenone (DRSP) 4 mg for 24 days followed by 4 days of placebo
Trial: 32598387
Drug: Desogestrel (DSG)
RxNorm normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desogestrel (DSG) 0.075 mg per day continuously
Trial: 35794811
Drug: Home-based vestibular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based vestibular rehabilitation therapy (Bal Ex)
Trial: 35794811
Drug: Hospital-based vestibular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-based vestibular rehabilitation therapy (control)
Trial: 33790161
Drug: Gemcitabine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1,000 mg/m2) and Cisplatin (40 mg/m2) on days 1 and 15, and Bevacizumab (15 mg/kg) on day 1, repeated every 4 weeks
Trial: 33790161
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus Cisplatin plus Bevacizumab combination chemotherapy
Trial: 33225971
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow (NHF) at 1.5 L/kg PBW/min (75–120 L/min)
Trial: 34641896
Drug: Direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral (DAA) treatment
Trial: 34800819
Drug: OJ (orange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OJ (orange juice containing 345 mg of hesperidin; n=15)
Trial: 34800819
Drug: EOJ (enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOJ (enhanced orange juice containing 600 mg of hesperidin; n=11)
Trial: 32633157
Drug: Everolimus with
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus with reduced calcineurin inhibitor (EVR+rCNI)
Trial: 34358497
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg and lamivudine 300 mg once daily
Trial: 32331737
Drug: Natural ointment
RxNorm normalized name: Boudreauxs Butt Paste Natural Ointment
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Natural ointment based on honey-tea tree oil
Trial: 35533197
Drug: Glutamate infusion
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate infusion
Trial: 36791792
Drug: Risperidone treatment
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone treatment
Trial: 34653814
Drug: Endometrial scratching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial scratching (twice endometrial sampling in follicular and luteal phases)
Trial: 33327326
Drug: Peony and
RxNorm normalized name: DEXPANTHENOL 0.2 g in 100 mL / SALICYLIC ACID 0.2 g in 100 mL / NIACINAMIDE 0.1 g in 100 mL TOPICAL SHAMPOO [CH6 Perfumed Aloforthya Peony and the sunset]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peony and licorice decoction (PLD) fumigation treatment
Trial: 33327326
Drug: Placebo fumigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo fumigation treatment
Trial: 33327326
Drug: PLD fumigation
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD fumigation treatment
Trial: 35654684
Drug: Vasopressin injection
RxNorm normalized name: Vasopressin Injection
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin injection
Trial: 33377451
Drug: Low-dose corticosteroids
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose corticosteroids
Trial: 33906081
Drug: kMCT (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: kMCT (30 g/day)
Trial: 33123219
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment for 12 months
Trial: 34942085
Drug: Tezacaftor 100
RxNorm normalized name: tezacaftor 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezacaftor 100 mg orally once daily plus ivacaftor 150 mg orally every 12 h
Trial: 34077535
Drug: NRT +
RxNorm normalized name: Nicotine Replacement Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRT + prescription medication
Trial: 32725447
Drug: Scapular-focused treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scapular-focused treatment with feedback (SFTF)
Trial: 32725447
Drug: Scapular-focused treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scapular-focused treatment without feedback (SFT)
Trial: 32699034
Drug: Belimumab 10
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab 10 mg/kg intravenous every 4 weeks
Trial: 34913216
Drug: Paper voucher
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper voucher described as redeemable for free follow-up and prescription glasses
Trial: 34913216
Drug: Standard referral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard referral for a free follow-up appointment and prescription glasses
Trial: 33731062
Drug: Active study
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active study product (combination of Bifidobacterium breve M‐16V, short‐chain galacto‐oligosaccharides, long‐chain fructo‐oligosaccharides and L‐glutamine)
Trial: 39110421
Drug: Standard therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapies
Trial: 34242463
Drug: Treatment Access
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Access Pathway (TAP)
Trial: 32575450
Drug: Bioactive compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioactive compounds (shaftoside, iso‐orientin, and orientin)
Trial: 33191527
Drug: High-glucose mixed-nutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-glucose mixed-nutrient meal ingestion (1.1 g glucose/kg body weight; 45% carbohydrate, 20% protein, 35% fat)
Trial: 33271093
Drug: HPV 16/18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV 16/18 AS04‐adjuvanted vaccine
Trial: 36170326
Drug: Oral amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amino acid challenge (AAC)
Trial: 36170326
Drug: Isocaloric glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric glucose solution (GS)
Trial: 39229259
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of IIV4 and PPV23
Trial: 34607600
Drug: Oral immunomodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunomodulation with UTI-relevant Escherichia coli lysate (Uro-Vaxom) for 90 days
Trial: 35718535
Drug: Acitretin Capsules
RxNorm normalized name: Acitretin Capsules
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acitretin Capsules and Calcipotriol Ointment
Trial: 33789592
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg
Trial: 32033922
Drug: LSD (13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD (13 μg)
Trial: 37323099
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg subcutaneously every 6 months)
Trial: 34109545
Drug: Coached clinics
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coached clinics (received online toolkit plus weekly assistance from a distance coach for 12 months)
Trial: 33020648
Drug: Spartalizumab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spartalizumab (400 mg every 4 weeks) + Dabrafenib (150 mg twice daily) + Trametinib (2 mg once daily)
Trial: 34350657
Drug: Short wavelength
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short wavelength bright light therapy (BLT)
Trial: 34350657
Drug: Long wavelength
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long wavelength bright light therapy (BLT)
Trial: 35030011
Drug: Spartalizumab 400
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily
Trial: 35030011
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily
Trial: 32696895
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) with antidepressants
Trial: 33120777
Drug: Antidepressants only
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants only (Control)
Trial: 33952735
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of vegetable oil of Vitis vinifera L. or Persea americana L. (10 mL)
Trial: 34764637
Drug: Remimazolam (a
RxNorm normalized name: remimazolam (as besylate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam (a bolus of 0.1 mg kg‐1, iv)
Trial: 34764637
Drug: Lidocaine (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (a bolus of 0.5 mg kg‐1, iv)
Trial: 32584935
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of UDCA
Trial: 32584935
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of UDCA
Trial: 37806651
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg daily
Trial: 33912695
Drug: Standard systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systemic therapy
Trial: 32632956
Drug: PUVA maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA maintenance treatment
Trial: 35258839
Drug: TA-ER 32
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-ER 32 mg
Trial: 35258839
Drug: TAcs 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAcs 40 mg
Trial: 35034431
Drug: Gadolinium injection
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium injection at 1 times dose (Group A)
Trial: 35034431
Drug: Gadolinium injection
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium injection at 1.5 times dose (Group B)
Trial: 35034431
Drug: Gadolinium injection
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium injection at 2 times dose (Group C)
Trial: 33757719
Drug: Sham cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham cupping therapy
Trial: 33472211
Drug: Oxytocin challenge
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin challenge test (OCT) - infusion of oxytocin 5 IU/500 mL Ringer lactate at a rate of 12 mL/h, doubling every 10 min until inducing 5 uterine contractions per 15-min interval.
Trial: 37830344
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin
Trial: 34837528
Drug: Peloid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peloid therapy (5 days a week for 3 weeks at 45 °C for 30 min each day)
Trial: 34837528
Drug: Peloid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peloid therapy
Trial: 34837528
Drug: Kinesio taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio taping (6 treatment days 2 times a week)
Trial: 32663119
Drug: 30 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 Gy in 5 once-weekly fractions of 6.0 Gy
Trial: 32663119
Drug: 28.5 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28.5 Gy in 5 once-weekly fractions of 5.7 Gy
Trial: 32653055
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream 1.5% twice daily
Trial: 32653055
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream 1.5% once daily
Trial: 32653055
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream 0.5% once daily
Trial: 32653055
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream 0.15% once daily
Trial: 32653055
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream (all doses)
Trial: 36107535
Drug: Liriope platyphylla
RxNorm normalized name: Liriope spicata tuber extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liriope platyphylla extract (LP) 1000 mg per day for 4 weeks
Trial: 36107535
Drug: Placebo (dextrin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dextrin) 1000 mg per day for 4 weeks
Trial: 34585252
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg intrathecal methotrexate
Trial: 34585252
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intrathecal methotrexate
Trial: 39363320
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy
Trial: 33449392
Drug: Lovastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 80 mg/day
Trial: 35802191
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate air‐powder abrasion supplemented by amino acid buffered hypochlorite solution (test-group 2)
Trial: 32967877
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m²) followed by intravenous immunoglobulin (IVIg) with an initial dose of 2 g/kg and 1.5 g/kg injections once a month for 5 months (maximum dose: 100 g)
Trial: 32967877
Drug: Rituximab alone
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab alone (375 mg/m²)
Trial: 34044830
Drug: Butorphanol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 2.5 μg/kg
Trial: 34044830
Drug: Butorphanol 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 5 μg/kg
Trial: 34044830
Drug: Butorphanol 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 7.5 μg/kg
Trial: 34044830
Drug: Butorphanol 10
RxNorm normalized name: butorphanol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 10 μg/kg
Trial: 33750085
Drug: Telerehabilitation (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telerehabilitation (8 weeks, 5 days/week, daily cost of 74 PLN)
Trial: 35209847
Drug: Fentanyl 8.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 8.3 μg/kg
Trial: 35209847
Drug: Oxycodone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.5 mg/kg
Trial: 35209847
Drug: Butorphanol 0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 0.16 mg/kg
Trial: 34446504
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg spironolactone daily, increasing to 100 mg until week 24
Trial: 32454209
Drug: 10 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/70 kg psilocybin
Trial: 36342289
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BJ) 12 ml twice daily
Trial: 33507722
Drug: Daily GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily GnRH agonist for luteal phase support (0.2 mg subcutaneous injection bid) following GnRH agonist trigger
Trial: 33507722
Drug: Standard strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard strategy (hCG trigger [10000 IU] and progesterone bid [400 mg/BD] for LPS)
Trial: 32966811
Drug: Surufatinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib (300 mg per day)
Trial: 34450042
Drug: Hypothermia treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermia treatment for moderate or severe neonatal encephalopathy
Trial: 34619073
Drug: Treatment rationale
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment rationale for iCBT
Trial: 34619073
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment rationale for iCBT
Trial: 32253184
Drug: Bimekizumab 64
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Bimekizumab 64 mg
Trial: 32253184
Drug: Bimekizumab 160
RxNorm normalized name: Bimekizumab 160 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab 160 mg
Trial: 32253184
Drug: Bimekizumab 320
RxNorm normalized name: bimekizumab 320 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Bimzelx]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab 320 mg
Trial: 35619097
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of feedback modifications
Trial: 34129601
Drug: Pyronaridine-artesunate, fixed-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyronaridine-artesunate, fixed-dose, once daily for 3 days, dosed by body weight, using tablet formulation for adults/adolescents and pediatric granule formulation for children/infants under 20 kg.
Trial: 34610286
Drug: 20% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% hypertonic dextrose injection
Trial: 36237908
Drug: Zilver PTX
RxNorm normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilver PTX drug-eluting stent (DES)
Trial: 36104179
Drug: LIPUS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIPUS therapy (1.3 MPa, 32 cycles, 5% duty cycle, 1 hour, 3 times a week for 6 sessions over 1.5 years)
Trial: 36104179
Drug: LIPUS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIPUS therapy
Trial: 35124675
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care primary healthcare treatment
Trial: 32590064
Drug: Thigh-high compression
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thigh-high compression stockings (CS) and sequential compression devices (SCDs)
Trial: 32590064
Drug: Sequential compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential compression devices (SCDs) alone
Trial: 36307040
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg/kg every 2 weeks)
Trial: 32294530
Drug: Durvalumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab plus tremelimumab (durvalumab 20 mg/kg q4w plus tremelimumab 1 mg/kg q4w × 4, then durvalumab 10 mg/kg q2w)
Trial: 33704831
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (medical treatment alone)
Trial: 33030225
Drug: Low-Dose, Open
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Dose, Open Food Challenge
Trial: 36364716
Drug: Food guiding
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food guiding booklet (G)
Trial: 36364716
Drug: Monthly income
RxNorm normalized name: Lincomed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly income of 3000−5000
Trial: 33992562
Drug: Baroreflex Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baroreflex Activation Therapy (BAT) plus guideline-directed medical therapy (GDMT)
Trial: 35143442
Drug: Platelet-Rich Plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-Rich Plasma (PRP) therapy combined with 4% hydroquinone (HQ) cream
Trial: 35143442
Drug: 4% hydroquinone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% hydroquinone (HQ) cream alone